SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva),

Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory

Biotechnology investing is a strange corner of the market. A company can own a drug that may even

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva),

5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ: A

ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get F

Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to dr

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical

Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared t

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical

Cracker Barrel (CBRL) stock rises in pre-market trading after reporting better-than-expected Q3 resu

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meanin

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meanin

/PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a do

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-

Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combi

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a

Veteran biotechnology executive with more than 20 years of leadership experience spanning research,

Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the

Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Ove

Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and

Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3

HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) are down on Friday as the company announced ini

Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million priva

RKLB: 8% | Rocket Lab shares are trading higher after the company reported better-than-expected Q1 s

SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a

On May 8, 2026, the Company delivered written notice to Leerink Partners LLC ("Leerink") tha

Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.95) per share which missed the

Initial AlloNK (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthr

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patien

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains

Dow futures up 250 points. Sonoco Products Co (SON) shares down 5.7% in pre-market after reporting l

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains

Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.84) per share which missed the

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose m

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mi

HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as